ARVN - NASDAQ

Arvinas, Inc.

ARVN·NASDAQ

$7.70

-3.8%

HealthcareBiotechnology

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$496.81M

EPS-1.2800

P/E Ratio-6.02

Earnings Date07/30/2026

arvn

Sales/Maturities of Investments

Last Annual Value

763.70M

3-Year CAGR

-12%

5-Year CAGR

29%

10-Year CAGR

46%

Adjust for Inflation

Arvinas, Inc. Competitors Analysis of Sales/Maturities of Investments

ARVN · NASDAQ

Company	Sales/Maturities of Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Arvinas, Inc. NASDAQ:ARVN	763.70M	-13.1%	11.9%	46.4%
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	874.25M	15.0%	N/A	N/A
Geron Corporation NASDAQ:GERN	411.72M	11.6%	10.5%	11.5%
Iovance Biotherapeutics, Inc. NASDAQ:IOVA	400.00M	11.9%	-12.1%	12.7%
Replimune Group, Inc. NASDAQ:REPL	386.48M	-4.5%	13.4%	N/A
Erasca, Inc. NASDAQ:ERAS	261.03M	2.1%	34.1%	N/A
Astria Therapeutics, Inc. NASDAQ:ATXS	4.05B	25.3%	133.0%	63.1%
Ginkgo Bioworks Holdings, Inc. NYSE:DNA	185.38M	N/A	N/A	N/A
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	201.71M	100.6%	N/A	N/A
MeiraGTx Holdings plc NASDAQ:MGTX	0.00	N/A	N/A	N/A

Arvinas, Inc. Fair Value Envelope

ARVN · NASDAQ

Our analysis suggests that ARVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.7, this represents a potential HIDDEN relative to our calculated worth for Arvinas, Inc..

HIDDEN

Intrinsic Value

Current Price: $7.7

Related Guides

Blog Categories

Continue your ARVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.